{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:52:45Z","timestamp":1784307165982,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open access funding provided by Medical University of Vienna"},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40261-025-01453-8","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T10:38:11Z","timestamp":1752316691000},"page":"551-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"45","clinical-trial-number":[{"clinical-trial-number":"nct05489224","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gerd","family":"Burmester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Trefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Racewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Jaworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Krogulec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Jeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kolossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Krajewska-W\u0142odarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Hrycaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr Adrian","family":"Klimiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungHyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeeHye","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GoEun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunAh","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YooBin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GaHee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"1453_CR1","doi-asserted-by":"publisher","first-page":"1255533","DOI":"10.3389\/fimmu.2023.1255533","volume":"14","author":"E Grebenciucova","year":"2023","unstructured":"Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023;14:1255533. https:\/\/doi.org\/10.3389\/fimmu.2023.1255533.","journal-title":"Front Immunol"},{"key":"1453_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155742","volume":"149","author":"M Jarlborg","year":"2022","unstructured":"Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022;149: 155742. https:\/\/doi.org\/10.1016\/j.cyto.2021.155742.","journal-title":"Cytokine"},{"issue":"3","key":"1453_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","volume":"7","author":"EG Favalli","year":"2020","unstructured":"Favalli EG. Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 2020;7(3):473\u2013516. https:\/\/doi.org\/10.1007\/s40744-020-00219-2.","journal-title":"Rheumatol Ther."},{"issue":"6","key":"1453_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3899\/jrheum.120687","volume":"40","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gomez-Reino J, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40(6):768\u201380. https:\/\/doi.org\/10.3899\/jrheum.120687.","journal-title":"J Rheumatol"},{"key":"1453_CR5","unstructured":"European Medicines Agency. RoActemra summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf. Accessed 5 Sept 2024."},{"key":"1453_CR6","unstructured":"US Food and Drug Administration. Actemra highlights of prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125472s049lbl.pdf. Accessed 5 Sept 2024."},{"issue":"1","key":"1453_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"1453_CR8","unstructured":"European Medicines Agency. Tyenne summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tyenne-epar-product-information_en.pdf. Accessed 5 Sept 2024."},{"key":"1453_CR9","unstructured":"US Food and Drug Administration. Tyenne highlights of prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761275Orig1s000Correctedlbl.pdf. Accessed 5 Sept 2024."},{"key":"1453_CR10","unstructured":"US Food and Drug Administration. Tofidence highlights of prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761354s000lbl.pdf. Accessed 5 Sept 2024."},{"issue":"5","key":"1453_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/13543784.2023.2212155","volume":"32","author":"KS Yu","year":"2023","unstructured":"Yu KS, Kim B, Shin D, Park MK, Hwang JG, Kim MG, et al. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Expert Opin Investig Drugs. 2023;32(5):429\u201339. https:\/\/doi.org\/10.1080\/13543784.2023.2212155.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"1453_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14712598.2024.2321360","volume":"24","author":"KS Yu","year":"2024","unstructured":"Yu KS, Ryu H, Shin D, Park M, Hwang J, Moon SJ, et al. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open-label, single-dose phase I study. Expert Opin Biol Ther. 2024;24(7):681\u20139. https:\/\/doi.org\/10.1080\/14712598.2024.2321360.","journal-title":"Expert Opin Biol Ther"},{"key":"1453_CR13","unstructured":"ClinicalTrials.gov. A study to evaluate usability of subcutaneous auto-injector of CT-P47 in patients with active rheumatoid arthritis. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05725434?term=CT-P47&rank=2. Accessed 9 Oct 2024."},{"issue":"2","key":"1453_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jcph.6139","volume":"65","author":"M Haranaka","year":"2025","unstructured":"Haranaka M, Eto T, Tanaka T, Yazawa R, Burmester G, Keystone E, et al. Pharmacokinetics and safety of intravenous candidate biosimilar CT-P47 and reference tocilizumab: a randomized, double-blind, phase 1 study. J Clin Pharmacol. 2025;65(2):233\u201341. https:\/\/doi.org\/10.1002\/jcph.6139.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1453_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004514","volume":"10","author":"JS Smolen","year":"2024","unstructured":"Smolen JS, Trefler J, Racewicz A, Jaworski J, Zielinska A, Krogulec M, et al. Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 2024;10(4): e004514. https:\/\/doi.org\/10.1136\/rmdopen-2024-004514.","journal-title":"RMD Open"},{"issue":"6","key":"1453_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/annrheumdis-2013-204948","volume":"74","author":"MH Buch","year":"2015","unstructured":"Buch MH, Silva-Fernandez L, Carmona L, Aletaha D, Christensen R, Combe B, et al. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis. 2015;74(6):963\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204948.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1453_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard-2022-223413","volume":"82","author":"P Studenic","year":"2023","unstructured":"Studenic P, Aletaha D, de Wit M, Stamm TA, Alasti F, Lacaille D, et al. American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis. 2023;82(1):74\u201380. https:\/\/doi.org\/10.1136\/ard-2022-223413.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1453_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","volume":"31","author":"DM van der Heijde","year":"1992","unstructured":"van der Heijde DM, van Riel PL, van Leeuwen MA, van\u2019t Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol. 1992;31(8):519\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/31.8.519.","journal-title":"Br J Rheumatol"},{"issue":"3","key":"1453_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702\u201310. https:\/\/doi.org\/10.1002\/art.21678.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1453_CR20","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1136\/ard.2011.153734","volume":"70","author":"D Aletaha","year":"2011","unstructured":"Aletaha D, Alasti F, Smolen JS. Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. Ann Rheum Dis. 2011;70(11):1975\u201380. https:\/\/doi.org\/10.1136\/ard.2011.153734.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1453_CR21","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1002\/art.23733","volume":"58","author":"D Aletaha","year":"2008","unstructured":"Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum. 2008;58(9):2622\u201331. https:\/\/doi.org\/10.1002\/art.23733.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1453_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12874-023-01926-4","volume":"23","author":"Z Salis","year":"2023","unstructured":"Salis Z, Gallego B, Sainsbury A. Researchers in rheumatology should avoid categorization of continuous predictor variables. BMC Med Res Methodol. 2023;23(1):104. https:\/\/doi.org\/10.1186\/s12874-023-01926-4.","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"1453_CR23","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959\u201364. https:\/\/doi.org\/10.1182\/blood-2008-05-155846.","journal-title":"Blood"},{"issue":"6","key":"1453_CR24","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078\u201385. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210297.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1453_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jbspin.2016.04.013","volume":"84","author":"J Sigaux","year":"2017","unstructured":"Sigaux J, Hamze M, Daien C, Morel J, Krzysiek R, Pallardy M, et al. Immunogenicity of tocilizumab in patients with rheumatoid arthritis. Jt Bone Spine. 2017;84(1):39\u201345. https:\/\/doi.org\/10.1016\/j.jbspin.2016.04.013.","journal-title":"Jt Bone Spine"},{"issue":"1","key":"1453_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2019.1697679","volume":"16","author":"EMA Hensor","year":"2020","unstructured":"Hensor EMA, Conaghan PG. Time to modify the DAS28 to make it fit for purpose(s) in rheumatoid arthritis? Expert Rev Clin Immunol. 2020;16(1):1\u20134. https:\/\/doi.org\/10.1080\/1744666X.2019.1697679.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1453_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/art.27740","volume":"63","author":"JS Smolen","year":"2011","unstructured":"Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43\u201352. https:\/\/doi.org\/10.1002\/art.27740.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1453_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/art.39996","volume":"69","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C. Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheumatol. 2017;69(4):728\u201334. https:\/\/doi.org\/10.1002\/art.39996.","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01453-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T01:06:11Z","timestamp":1753923971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01453-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01453-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"28 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Medical University of Vienna. This study was funded by Celltrion, Inc. (Incheon, Republic of Korea). The study sponsor, Celltrion, Inc. (Incheon, Republic of Korea), played a role in the study design, data collection and analysis, decision to publish and preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gerd Burmester has received honoraria for consulting and lectures from Celltrion, Inc., Chugai, Fresenius and Sanofi. Marek Krogulec has received support for meeting attendance from Accord, Egis, Medac and Sandoz. S\u0142awomir Jeka has received consulting fees from AbbVie, Celltrion, Inc., Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi and UCB; and payments or honoraria from AbbVie, Celltrion, Inc., Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi and UCB. Rafa\u0142 Wojciechowski has received speaker fees from Eli Lilly, Janssen, Novartis, SOBI and UCB; support for meeting attendance from AbbVie; and is involved in the leadership of the Polish Rheumatology Society. Magdalena Krajewska-W\u0142odarczyk has received payments or honoraria from AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Medac, MSD, Novartis, Pfizer, Sandoz, SOBI and UCB; and support for meeting attendance from AbbVie, Medac, Novartis, Pfizer and SOBI. Pawe\u0142 Hrycaj has received research grants from Celltrion, Inc. SungHyun Kim is an employee of Celltrion, Inc. JeeHye Suh, GoEun Yang, YunAh Kim, YooBin Jung and GaHee Park are employees of Celltrion, Inc., and hold stocks in Celltrion, Inc. Josef S. Smolen has received payments to his institution from AbbVie, AstraZeneca, Eli Lilly, Novartis, Galapagos and Roche; personal fees from AbbVie, Amgen, Ananda, Astro, BMS, Celltrion, Inc., Chugai, Eli Lilly, Gilead, Immunovant, MSD, Novartis, Pfizer, Roche, R-Pharma, Samsung, Sanofi and UCB; payments or honoraria from Eli Lilly; and support for meeting attendance from Eli Lilly. Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zieli\u0144ska, Katarzyna Kolossa, Anna Dudek and Piotr Adrian Klimiuk have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (and Good Clinical Practice Guideline). All national, state, and local laws or regulations were followed. Prior to study initiation, the study protocol, informed consent form, advertisements used for the recruitment of participants and any other written materials provided to participants were approved by the institutional review board. This study involves human participants and was approved by the Institutional Review Board, Komisja Bioetyczna przy OIL w Bia\u0142ymstoku, ul. \u015awi\u0119toja\u0144ska 7, 15-082 Bia\u0142ystok, Poland, and the Ethics Committee at the Regional Medical Chamber with its seat in Bia\u0142ystok, 15-082 Bia\u0142ystok, ul. \u015awi\u0119toja\u0144ska 7, Poland (reference number: 43\/2022\/VIII).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all patients prior to enrolment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data relevant to the study are included in the article or uploaded as supplementary information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"GB, SHK, JHS, GEY, YAK, YBJ, GHP and JSS contributed to the study design. JT, AR, JJ, AZ, MK, SJ, RW, KK, AD, MKW, PH, PAK, SHK, GEY, YBJ and GHP contributed to the data collection. All authors contributed to the data analysis or interpretation, critically reviewed and critically revised the manuscript, approved the final version for publication, and agree to be accountable for the accuracy and integrity of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}